Norfloxacinの男子淋菌性尿道炎に対する細菌学的検討と臨床効果

Abstract

1)本剤(NFLX)はキノロンカルボン酸系の新合成抗生剤である.2) 1984年5月～7月の間に男子淋菌性尿道炎患者から分離された淋菌39株中3株がβ-lactamase産生淋菌(PPNG)で, 36株はnon-PPNGであった.PPNG 3株に対するPCG (penicillin G)のMICは, 6.25～25 μg/mlに分布し, non-PPNG 36株では0.05～3.13 μg/mlに分布していた.NFLXのMICは, PPNGでは0.025～0.1 μg/mlに, non-PPNGでは≦0.0125～0.2 μg/mlに分布し, 両群に対して優れた抗菌力を示した.3)男子淋菌性尿道炎の30例に対して, 本剤を1回2錠1日3回, 3日間経口投与し, 著効12, 有効18例であった.なお, PPNG症例が3例含まれていたが, 本剤投与により全て治癒した.副作用はなかった

Thirty male patients with gonorrheal urethritis were treated with norfloxacin (NFLX) at our urological ward between May and July, 1984, and clinically evaluated. Thirty-nine strains of Neisseria gonorrhoeae isolated from the clinical specimens of these patients were bacteriologically studied. Of the 39 strains, 3 (7.7%) were PPNG strains and the other 36 strains were non-PPNG strains. The minimum inhibitory concentration (MIC) of penicillin G, PCG to the 3 PPNG strains was 6.25-25 micrograms/ml and that to the 36 non-PPNG strains was 0.05-3.13 micrograms/ml. The MIC of NFLX to the PPNG strains was 0.025-0.1 microgram/ml and that to the non-PPNG strains was less than or equal to 0.0125-0.2 microgram/ml. The patients with gonorrheal urethritis were given NFLX orally for 3 days at a daily dose of 600 mg. The clinical efficacy rate was 100%: excellent in 12 and good in 18 cases. All 3 patients with gonorrheal urethritis caused by PPNGs were cured. No subjective side effects were found.